|Active Ingredient (Brand Name)||Disease Area||Marketing Authorisation|
|Chenodeoxycholic acid (Chenodeoxycholic acid Leadiant)||Cerebrotendinous Xanthomatosis||UK, EU, Israel, Switzerland*, Chile*, Colombia*|
|Procarbazine (Natulan)||Hodgkin Disease, Non-Hodgkin Lymphomas, Brain Tumours, Chronic Lymphocytic Leukaemia, Small Cell Lung Cancer**||France, Spain, Germany, Italy, Russia, Netherlands, Switzerland*, Hong Kong*, China, Australia|
Brand names may differ in different countries
*Marketing Authorisations held by partner organisations
**Indications may differ between countries and each indication may not be authorised in every country
Last update: July 2022
For patients: if you wish to report an adverse event related to one of our products, please contact your healthcare provider. In addition, you can contact us on email@example.com.
For healthcare professionals: if you wish to report an adverse event related to one of our products, please follow the current regulatory procedure in force in your country or contact us at firstname.lastname@example.org.
If your residence is in the U.S. or Canada, please consult the North American website for details on safety reporting.